Wells Fargo maintains PTC Therapeutics at Overweight, raises price target to $112 from $109

What happened

Wells Fargo kept its Overweight rating on PTC Therapeutics and raised its price target to $112 from $109, a 2.8% increase. The new target implies 73.8% upside from the October 29 close of $64.46.

Confirmed

Global impact / market context

An Overweight rating means the analyst expects the stock to beat the average of covered stocks. A higher target signals more expected profit, which can draw buyer interest and support the share price.

Analyst inference

The $112 target sits far above the $64.46 close, showing the analyst sees large potential gains. Such a wide gap can reflect optimism that may or may not be met, so the stock could stay volatile.

Analyst inference

What to watch

1. Watch whether the share price moves toward the $112 target from the October 29 close of $64.46, which would show the analyst view gaining acceptance. Confirmed
2. Watch whether other analysts change their ratings or price targets for PTC Therapeutics, since a shared shift could strengthen or weaken the upgraded view. Proposed
3. Watch company updates on drug progress and spending, because new results could either support the analyst's higher target or push expectations back down. Analyst inference

Evidence

• Original source link unavailable